Abstract
The development of cardiovascular calcifications in chronic kidney disease (CKD) patients involves multiple risk factors with additive effects. However, a number of questions concerning cardiovascular calcifications in CKD patients remain unanswered at present due to lack of clinical data or due to the impossibility of conducting clinical trials to investigate these issues. In this review, we discuss how animal models could help us understand better the pathophysiology and management of calcifying cardiovascular complications associated with CKD.
MeSH terms
-
Animals
-
Bone Density Conservation Agents / pharmacology
-
Calcinosis / etiology
-
Calcinosis / metabolism
-
Calcinosis / physiopathology*
-
Calcinosis / prevention & control*
-
Cardiovascular Diseases / etiology
-
Cardiovascular Diseases / metabolism
-
Cardiovascular Diseases / physiopathology*
-
Cardiovascular Diseases / prevention & control*
-
Chelating Agents / pharmacology
-
Disease Models, Animal
-
Disease Progression
-
Humans
-
Kidney Failure, Chronic / complications
-
Kidney Failure, Chronic / metabolism
-
Kidney Failure, Chronic / physiopathology*
-
Polyamines / pharmacology
-
Sevelamer
-
Vitamin D / metabolism
-
Vitamin D / pharmacology
Substances
-
Bone Density Conservation Agents
-
Chelating Agents
-
Polyamines
-
Vitamin D
-
Sevelamer